Guidelines for using body composition measurement in patients with human immunodeficiency virus infection

AIDS Patient Care and STDs

Volumn 16, Issue 8, 2002, Pages 375-388

  Wanke, Christine ^a   Polsky, Bruce ^b   Kotler, Donald ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHROPOMETRY; BODY COMPOSITION; CAREGIVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRACTICE GUIDELINE; REVIEW; WASTING SYNDROME;

ANTHROPOMETRY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; ELECTRIC IMPEDANCE; HIV WASTING SYNDROME; HUMANS; PRACTICE GUIDELINES;

EID: 0036337865     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/10872910260196404     Document Type: Review

References (79)

1. Body composition studies in patients with the acquired immunodeficiency syndrome
2. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome
3. Magnitude of body-cell mass depletion and the timing of death from wasting in AIDS
4. Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS
5. Relationships among nutritional status, disease progression, and survival in HIV infection
6. Weight loss prior to clinical AIDS as a predictor of survival
7. Change in body weight (WT) as a predictor of death and opportunistic complications (OC) in HIV by history of prior OC
8. Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients
9. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes
10. Nutritional status and quality of life
11. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
12. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
13. Fat distribution and metabolic changes in patients with HIV infection
14. Measurement of body weight and BCM in patients receiving highly active antiretroviral therapy (HAART)
15. Changes in AIDS-defining illnesses in a London Clinic, 1987-1998
16. Treatment guidelines for HIV-associated wasting
17. The effect of protease inhibitors on weight and body composition in HIV-infected patients
18. Buffalo hump" in men with HIV-1 infection
19. Treatment of dorsocervical fat pads and truncal adiposity with Serostim (recombinant human growth hormone) in patients with AIDS maintained on HAART
20. Visceral abdominal-fat accumulation associated with use of indinavir
21. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging
22. Variation in body weight and plasma viral load in HIV patients treated with tritherapy including a protease inhibitor
23. Correlation between body composition, caloric intake and plasma viral load in HIV infected patients
24. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy
25. Loss of LBM is common in HIV-infected adults
26. Cross-sectional and longitudinal evaluation of body composition in men with HIV infection
27. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting
28. Nutritional assessment by anthropometric and biochemical methods
29. Resting energy expenditure, caloric intake, and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome
30. Time-dependent variation in weight and body composition in healthy adults
31. The role of body composition measurements in wasting syndromes
32. A placebo-controlled trial of megestrol acetate in patients with AIDS-related anorexia and cachexia
33. Effects of megestrol acetate upon body composition and circulating testosterone in patients with AIDS
34. Growth hormone therapy of AIDS wasting
35. The five-level model: A new approach to organizing body-composition research
36. Chemical and elemental analysis of humans in vivo using improved body composition models
37. Body fat assessed from total body density and its estimation from skinfold thickness: Measurement on 481 men and women aged from 16 to 72 years
38. Anthropometric assessment of fat-free body mass
39. Bioelectrical impedance analysis in body composition measurement: National Institutes of Health technology assessment conference statement: December 12-14, 1994
40. Bioelectrical impedance analysis: A review of principles and applications
41. Fat-free mass in chronic illness: Comparison of bioelectrical impedance and dual-energy x-ray absorptiometry in 480 chronically ill and healthy subjects
42. Techniques used in the measurement of body composition: An overview with emphasis on bioelectrical impedance analysis
43. Bioelectrical impedance methods in clinical research: A followup to the NIH technology assessment conference
44. Bioelectrical impedance analysis (BIA) in HIV infection: Principles and clinical applications
45. Clinical characteristics influencing bioelectrical impedance analysis measurements
46. Body composition analysis by bioelectrical impedance: Effect of skin temperature
47. Sources of variability in bioelectrical impedance determinations in adults
48. Techniques for the measurement of body composition: A practical guide
49. Body composition in Pima Indians: Validation of bioelectrical resistance
50. Factors affecting bioelectrical impedance measurements in humans
51. The menstrual cycle's effect on the reliability of bioimpedance measurements for assessing body composition
52. Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: Effects of race, sex, and disease
53. Bioelectrical impedance analysis as a predictor of survival in patients with human immunodeficiency virus infection
54. Early changes of body composition in human immunodeficiency virus-infected patients: Tetrapolar body impedance analysis indicates significant malnutrition
55. Phase angle from bioelectrical impedance analysis remains an independent predictive marker in HIV-infected patients in the era of highly active antiretroviral treatment
56. Bioelectrical impedance analysis in HIV-infected patients treated with triple antiretroviral treatment
57. Assessment of intracellular water by whole body bioelectrical impedance and total body potassium in HIV-positive patients
58. Comparison of total body potassium with other techniques for measuring LBM in men and women with AIDS wasting
59. Body composition in patients with acquired immunodeficiency syndrome: A validation study of bioelectric impedance analysis
60. Validation of bioimpedance analysis as a measure of change in body cell mass as estimated by whole-body counting of potassium in adults
61. Bioelectrical impedance analysis: A way to assess changes in body cell mass in patients with acquired immunodeficiency syndrome?
62. Epidemiological and clinical aspects of the metabolic complications of HIV infection: The fat redistribution syndrome
63. Bioimpedance analysis: Potential for measuring lower limb skeletal muscle mass
64. Estimation of skeletal muscle mass by bioelectrical impedance analysis
65. Why bioelectrical impedance should be used for estimated adiposity
66. Body-fat measurement in patients with acquired immunodeficiency syndrome: Which method should be used?
67. Measurement of total body fat by underwater weighing: New insights and uses for old method
68. Monitoring changes in fat-free mass in HIV-positive men with hypotestosteronemia and AIDS wasting syndrome treated with gonadal hormone replacement therapy
69. Use of dual-energy x-ray absorptiometry in body composition studies: Not yet a gold standard
70. Appendicular skeletal muscle mass: Measurement by dual-photon absorptiometry
71. Pathophysiology of the AIDS wasting syndrome
72. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging
73. Skeletal muscle Mass: Evaluation of neutron activation and dual-energy X-ray absorptiometry methods
74. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing anti-retroviral therapy: Preliminary results of the LIPOCO study
75. Reliability of in vivo neutron activation analysis for measuring body composition: Comparisons with tracer dilution and dual-energy x-ray absorptiometry
76. Longitudinal changes in body composition measured with a variety of methods in patients with AIDS